

Consolidated Financial Results for the Third Quarter of FY2018

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2017 Q3 Apr. 2017-Dec. 2017		FY2018 Q3 Apr. 2018-Dec. 2018		YoY
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	38,713	100.0%	37,016	100.0%	95.6%
Cost of Sales	23,351	60.3%	22,027	59.5%	94.3%
Gross Profit	15,362	39.7%	14,988	40.5%	97.6%
Selling, General and Administrative Expenses	11,902	30.7%	12,404	33.5%	104.2%
Operating Income	3,460	8.9%	2,578	7.0%	74.5%
Profit Attributable to Owners of Parent	3,026	7.8%	2,216	6.0%	73.2%

Forecast of Consolidated Financial Results for the FY2018

	FY2017 Actual Apr. 2017-Mar. 2018		FY2018 Forecast Apr. 2018-Mar. 2019	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	48,994	100.0%	48,000	100.0%
Operating Income	2,824	5.8%	2,000	4.1%
Profit Attributable to Owners of Parent	2,388	4.9%	1,600	3.3%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2017 Q3 Actual	FY2018 Q3 Actual	FY2018 Forecast
Antihypertensive agent	CANDESARTAN*	104.5	94.2	122.2
Thyroid hormone	THYRADIN	41.3	45.8	59.4
Hyperlipidemic agent	LIPDIL	34.2	16.4	18.9
LH-RH derivative	LEUPRORELIN	32.3	32.7	42.7
Prostate cancer therapeutic agent	BICALUTAMIDE	12.8	9.6	12.4
Antihypertensive agent	AMLODIPINE	12.6	10.9	14.1
Emergency contraceptive	NORLEVO	9.3	10.1	12.7
Antithyroid agent	MERCAZOLE	8.6	9.2	11.9
Poorly absorbable antimicrobial agent	RIFXIMA	7.1	19.0	26.3

※ Including CANDESARTAN formulation's sales